ZeNix
Bedaquiline-Pretomanid-Linezolid Regimens for MDR/XDR-TB
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 181 patients with MDR or XDR tuberculosis, BPaL with linezolid 600 mg for 26 weeks preserved favourable outcome while reducing toxicity compared with linezolid 1200 mg for 26 weeks.
N
181
Disegno
Phase 3 dose-finding RCT
Esito
Favourable outcome at 6 months post-treatment
Rilevanza
3
RisultatoFavourable outcome ~91% in linezolid-600/26-wk arm; overall risk-benefit favoured this arm (less peripheral neuropathy/myelosuppression, fewer dose modifications).
Conradie F, et al. N Engl J Med. 2022;387(9):810-823. 10.1056/NEJMoa2119430
Discussione e critica
Defined the optimal linezolid dose for BPaL — preserves efficacy and protects the peripheral nervous system.